Literature DB >> 22094231

Expression patterns of the immunosuppressive proteins PD-1/CD279 and PD-L1/CD274 at different stages of cutaneous T-cell lymphoma/mycosis fungoides.

Kanchan Kantekure, Yusong Yang, Puthiyaveettil Raghunath, Andras Schaffer, Anders Woetmann, Qian Zhang, Niels Odum, Mariusz Wasik.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22094231      PMCID： PMC3262090          DOI： 10.1097/DAD.0b013e31821c35cb

Source DB:  PubMed          Journal:  Am J Dermatopathol        ISSN： 0193-1091            Impact factor:   1.533


× No keyword cloud information.
  20 in total

Review 1.  Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity.

Authors:  Lieping Chen
Journal:  Nat Rev Immunol       Date:  2004-05       Impact factor: 53.106

2.  Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4-CD8-) thymocytes.

Authors:  H Nishimura; Y Agata; A Kawasaki; M Sato; S Imamura; N Minato; H Yagita; T Nakano; T Honjo
Journal:  Int Immunol       Date:  1996-05       Impact factor: 4.823

3.  Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity.

Authors:  Fumiya Hirano; Katsumi Kaneko; Hideto Tamura; Haidong Dong; Shengdian Wang; Masao Ichikawa; Cecilia Rietz; Dallas B Flies; Julie S Lau; Gefeng Zhu; Koji Tamada; Lieping Chen
Journal:  Cancer Res       Date:  2005-02-01       Impact factor: 12.701

4.  B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders.

Authors:  Ryan A Wilcox; Andrew L Feldman; David A Wada; Zhi-Zhang Yang; Nneka I Comfere; Haidong Dong; Eugene D Kwon; Anne J Novak; Svetomir N Markovic; Mark R Pittelkow; Thomas E Witzig; Stephen M Ansell
Journal:  Blood       Date:  2009-07-13       Impact factor: 22.113

5.  Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production.

Authors:  Julia A Brown; David M Dorfman; Feng-Rong Ma; Elizabeth L Sullivan; Oliver Munoz; Clive R Wood; Edward A Greenfield; Gordon J Freeman
Journal:  J Immunol       Date:  2003-02-01       Impact factor: 5.422

Review 6.  B7-H1 pathway and its role in the evasion of tumor immunity.

Authors:  Haidong Dong; Lieping Chen
Journal:  J Mol Med (Berl)       Date:  2003-04-30       Impact factor: 4.599

Review 7.  The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation.

Authors:  James L Riley; Carl H June
Journal:  Blood       Date:  2004-09-07       Impact factor: 22.113

8.  Absence of programmed death receptor 1 alters thymic development and enhances generation of CD4/CD8 double-negative TCR-transgenic T cells.

Authors:  Christian Blank; Ian Brown; Reinhard Marks; Hiroyuki Nishimura; Tasuku Honjo; Thomas F Gajewski
Journal:  J Immunol       Date:  2003-11-01       Impact factor: 5.422

9.  In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3.

Authors:  V H Sommer; O J Clemmensen; O Nielsen; M Wasik; P Lovato; C Brender; K W Eriksen; A Woetmann; C G Kaestel; M H Nissen; C Ropke; S Skov; N Ødum
Journal:  Leukemia       Date:  2004-07       Impact factor: 11.528

10.  Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.

Authors:  Haidong Dong; Scott E Strome; Diva R Salomao; Hideto Tamura; Fumiya Hirano; Dallas B Flies; Patrick C Roche; Jun Lu; Gefeng Zhu; Koji Tamada; Vanda A Lennon; Esteban Celis; Lieping Chen
Journal:  Nat Med       Date:  2002-06-24       Impact factor: 53.440
View more
  35 in total

1.  Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study.

Authors:  Michael S Khodadoust; Alain H Rook; Pierluigi Porcu; Francine Foss; Alison J Moskowitz; Andrei Shustov; Satish Shanbhag; Lubomir Sokol; Steven P Fling; Nirasha Ramchurren; Robert Pierce; Asa Davis; Richard Shine; Shufeng Li; Sophia Fong; Jinah Kim; Yi Yang; Wendy M Blumenschein; Jennifer H Yearley; Biswajit Das; Rajesh Patidar; Vivekananda Datta; Erin Cantu; Justine N McCutcheon; Chris Karlovich; P Mickey Williams; Priyanka B Subrahmanyam; Holden T Maecker; Steven M Horwitz; Elad Sharon; Holbrook E Kohrt; Martin A Cheever; Youn H Kim
Journal:  J Clin Oncol       Date:  2019-09-18       Impact factor: 44.544

Review 2.  Immune Dysfunction in Non-Hodgkin Lymphoma: Avenues for New Immunotherapy-Based Strategies.

Authors:  Lorenzo Falchi
Journal:  Curr Hematol Malig Rep       Date:  2017-10       Impact factor: 3.952

3.  Progression of mycosis fungoides occurs through divergence of tumor immunophenotype by differential expression of HLA-DR.

Authors:  Duncan Murray; Jack Luke McMurray; Suzy Eldershaw; Hayden Pearce; Nathaniel Davies; Julia J Scarisbrick; Paul Moss
Journal:  Blood Adv       Date:  2019-02-26

Review 4.  The role of cytokine signaling in the pathogenesis of cutaneous T-cell lymphoma.

Authors:  Ronnie M Abraham; Qian Zhang; Niels Odum; Mariusz A Wasik
Journal:  Cancer Biol Ther       Date:  2011-12-15       Impact factor: 4.742

Review 5.  PD-1/PD-L1 inhibitors in haematological malignancies: update 2017.

Authors:  Tomas Jelinek; Jana Mihalyova; Michal Kascak; Juraj Duras; Roman Hajek
Journal:  Immunology       Date:  2017-08-04       Impact factor: 7.397

Review 6.  PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.

Authors:  Aaron Goodman; Sandip P Patel; Razelle Kurzrock
Journal:  Nat Rev Clin Oncol       Date:  2016-11-02       Impact factor: 66.675

7.  Cutaneous T cell lymphoma expresses immunosuppressive CD80 (B7-1) cell surface protein in a STAT5-dependent manner.

Authors:  Qian Zhang; Hong Yi Wang; Fang Wei; Xiaobin Liu; Jennifer C Paterson; Darshan Roy; Daniela Mihova; Anders Woetmann; Andrzej Ptasznik; Niels Odum; Stephen J Schuster; Teresa Marafioti; James L Riley; Mariusz A Wasik
Journal:  J Immunol       Date:  2014-02-12       Impact factor: 5.422

8.  Primary T Cells from Cutaneous T-cell Lymphoma Skin Explants Display an Exhausted Immune Checkpoint Profile.

Authors:  Christiane Querfeld; Samantha Leung; Patricia L Myskowski; Shane A Curran; Debra A Goldman; Glenn Heller; Xiwei Wu; Sung Hee Kil; Sneh Sharma; Kathleen J Finn; Steven Horwitz; Alison Moskowitz; Babak Mehrara; Steven T Rosen; Allan C Halpern; James W Young
Journal:  Cancer Immunol Res       Date:  2018-06-12       Impact factor: 11.151

Review 9.  Enhancing antitumor immunity through checkpoint blockade as a therapeutic strategy in T-cell lymphomas.

Authors:  Alexander Neuwelt; Taha Al-Juhaishi; Eduardo Davila; Bradley Haverkos
Journal:  Blood Adv       Date:  2020-09-08

10.  Expression of the checkpoint receptors LAG-3, TIM-3 and VISTA in peripheral T cell lymphomas.

Authors:  Carlos A Murga-Zamalloa; Noah A Brown; Ryan A Wilcox
Journal:  J Clin Pathol       Date:  2019-10-31       Impact factor: 3.411
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.